Abstract
Cachexia is often associated with severe loss of skeletal muscle mass and a reduced energy metabolism. The maintenance of muscle mass can be generally regarded as a simple balance between protein synthesis and protein degradation. Several evidences are available in the current literature favoring a model in which myofilaments are released from the sarcomere by the action of calciumactivated calpains followed by the degradation of the myofilaments by the ubiquitin proteasome system. The initiation of the protein breakdown machinery is regulated by several factors like inflammatory cytokines, angiotensin II, insulin / insulin like growth factor 1 and reactive oxygen species. These factors also have the capability to influence PGC-1alpha activity, thereby regulating mitochondrial energy production. All these molecular alterations regulating muscle mass and energy production in the skeletal muscle finally leads to a reduction in exercise capacity in cachexia.
Keywords: Ubiquitin-proteasome-system (UPS), muscle protein balance, exercise training, cachexia, mitochondria, inflammatory cytokines, reactive oxygen species, atrophy, insulin, myostatin
Current Pharmaceutical Design
Title: Muscle Metabolism and Exercise Capacity in Cachexia
Volume: 17 Issue: 35
Author(s): Volker Adams, Stefan D. Anker and Gerhard Schuler
Affiliation:
Keywords: Ubiquitin-proteasome-system (UPS), muscle protein balance, exercise training, cachexia, mitochondria, inflammatory cytokines, reactive oxygen species, atrophy, insulin, myostatin
Abstract: Cachexia is often associated with severe loss of skeletal muscle mass and a reduced energy metabolism. The maintenance of muscle mass can be generally regarded as a simple balance between protein synthesis and protein degradation. Several evidences are available in the current literature favoring a model in which myofilaments are released from the sarcomere by the action of calciumactivated calpains followed by the degradation of the myofilaments by the ubiquitin proteasome system. The initiation of the protein breakdown machinery is regulated by several factors like inflammatory cytokines, angiotensin II, insulin / insulin like growth factor 1 and reactive oxygen species. These factors also have the capability to influence PGC-1alpha activity, thereby regulating mitochondrial energy production. All these molecular alterations regulating muscle mass and energy production in the skeletal muscle finally leads to a reduction in exercise capacity in cachexia.
Export Options
About this article
Cite this article as:
Adams Volker, D. Anker Stefan and Schuler Gerhard, Muscle Metabolism and Exercise Capacity in Cachexia, Current Pharmaceutical Design 2011; 17 (35) . https://dx.doi.org/10.2174/138161211798357746
DOI https://dx.doi.org/10.2174/138161211798357746 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine
Storm that Implicates for Therapeutic Strategies
Current Medicinal Chemistry Animal Models of Systemic Sclerosis
Current Pharmaceutical Design Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Is There an Association between Periodontitis and Hypertension?
Current Cardiology Reviews Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Fork Head Transcription Factors
Current Genomics Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Cadmium, Organ Toxicity and Therapeutic Approaches: A Review on Brain, Kidney and Testis Damage
Current Medicinal Chemistry Oxytocin and Diabetes Mellitus: A Strong Biochemical Relation. Review
Current Diabetes Reviews Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Current Psychiatry Reviews Neuroleptics and Migraine
Central Nervous System Agents in Medicinal Chemistry The Metabolic Syndrome and the Relevance of Nutrients for its Onset
Recent Patents on Biotechnology Pexelizumab and its Role in the Treatment of Myocardial Infarction and in Coronary Artery Bypass Graft Surgery: A Review
Recent Patents on Cardiovascular Drug Discovery Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Malignant Intracranial High Grade Glioma and Current Treatment Strategy
Current Cancer Drug Targets Understanding the Cardiovascular Actions of Soy Isoflavones: Potential Novel Targets for Antihypertensive Drug Development
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Aspect of Beta-Thalassaemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Synergistic Effects of Social Isolation and Morphine Addiction on Reduced Neurogenesis and BDNF Levels and the Resultant Deficits in Cognition and Emotional State in Male Rats
Current Molecular Pharmacology